CIT GAP Funds Invests in OxiWear to Support Innovations and Emergency Alerting for Pulmonary Hypertension
Richmond, VA, June 16, 2021 (GLOBE NEWSWIRE) -- The Center for Innovative Technology (CIT) today announced that CIT GAP Funds, the direct investment program of the Virginia Innovation Partnership Authority (VIPA) Investment Division, has invested in Arlington, Va.-based OxiWear. Provider of a wearable earpiece that monitors blood oxygen levels, OxiWear’s device alerts users when it falls below safe thresholds, allowing help to be called in time for treatment. OxiWear will use this investment to support growth, conduct further research, and expand relationships with more hospitals and pharmacies.
Ear-wearable device continuously monitors blood oxygen levels and alerts users if it falls below safe thresholds, preventing delays in assistance
“Currently, there is no other device available to continuously monitor oxygen levels. OxiWear is a game changer for those affected by the complications of pulmonary hypertension, and could be the difference between safety and danger,” said Tom Weithman, Managing Director of CIT GAP Funds. “Shavini and her team are in a great position to expand and reach more medical departments, nursing homes and more locations serving patients with PH. We are excited to support OxiWear in their endeavors and lifesaving mission.”
CIT Press 2020-2021